Who is venture debt actually for?
As conventionally practised, venture-backed companies: most venture lenders will not lend without an institutional sponsor on the register, because the underwriting rests on the syndicate rather than the company's own credit, on who led the last round, how much capital stands behind the company, and whether those investors would fund again (SVB, Carta and WilmerHale startup-financing guides, accessed 6 September 2026).
A company without institutional backing is not excluded from debt; it is looking at a different lender set. Growth-focused non-bank lenders underwrite revenue and traction where venture lenders underwrite sponsors (Flow Capital, accessed 6 September 2026), which is the territory of revenue-backed financing rather than venture debt. Knowing which category a company falls into before approaching anyone saves months of the wrong conversations.
For the companies it fits, the use case is precise: extending runway to a milestone the next round will price, a product release, a revenue threshold, a regulatory step, without selling equity at today's valuation to get there. The instrument is a bridge between priced events, and it behaves badly when treated as anything else.
What do venture lenders underwrite?
The syndicate first: the investors' names, their fund cycles, their reserves, and their concentration in the company. Then burn and runway under the board plan and a slower one; enterprise value against the proposed debt, read from the last round's pricing; and the credibility of the milestones the runway is meant to reach. The evidence set is the cap table, the round documents, the board-approved plan, and cohort-level operating data.
The term sheet turns less on the rate than on three other terms. The warrant, which is equity given away in the good outcome and deserves pricing as such. The draw structure, because committed tranches against milestones are worth more than a single funding a company must hold as cash. And the covenants that reference investor behaviour: material-adverse-change and investor-abandonment language is the real risk allocation in the document, deciding what happens if the syndicate's support wavers at exactly the moment the company needs the facility most.
Timing is part of the negotiation. Terms are strongest at or near an equity round, when the syndicate's commitment is freshest and the lender's underwriting question answers itself; raising venture debt long after the round, from need rather than strength, meets a different market (market convention).
What does the borrower actually have to decide?
Whether the debt funds a milestone or a delay. Venture debt drawn to reach a priced event arrives at the next round as evidence of discipline; the same debt drawn to fund a missed plan arrives as a problem senior to every shareholder. The instrument amplifies whatever trajectory it funds, which is why the decision to draw deserves the same rigour as the decision to raise.
How much to take: the milestone's cost with margin, not the maximum offered. Undrawn commitments cost commitment fees; drawn regret costs runway at the worst time. And what the warrant is worth: coverage, strike, and treatment on a sale are negotiated terms, and conceding them casually in a fast close is how a cheap facility becomes expensive in precisely the outcome everyone is working toward.
The comparison that frames all of it is against equity and against the newer revenue-based structures. Between rounds, the honest arithmetic sets the all-in cost of the debt, coupon, fees, and warrant, against the dilution of raising the same capital now, at the current valuation, and the linked positions carry that arithmetic in detail.